arrow
J

Jesper Falkesgaard Højen

novo nordisk a/s
H指数:16
被引数:1,441

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A quantitative method to estimate free interleukin-6 among patients treated with the interleukin-6 ligand inhibitor ziltivekimab: comparison to C-reactive protein with implications for the ZEUS, HERMES, and ARTEMIS cardiovascular outcomes trials

一种用于估算接受白细胞介素-6配体抑制剂ziltivekimab治疗的患者中游离白细胞介素-6的定量方法:与C反应蛋白的比较及其对ZEUS、HERMES和ARTEMIS心血管结局试验的启示

2026-05-280
PRE
International nomenclature guidelines for the IL-1 family of cytokines and receptors
2024-03-183
PRE
Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial

TLR9激动剂和广泛中和抗体对HIV-1持久性的影响: TITAN 2a期随机试验

2023-09-1123
OAAI
Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial
2021-05-01139
OAAI
SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses

SARS-CoV-2持久性与抗原特异性CD8 T细胞反应有关

2021-02-01100
OAAI
Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits &ITEx Vivo&IT Lipopolysaccharide-Induced Inflammatory Responses
MSPHERE
IF3.1
2018-02-2820
OAAI
Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection
2017-03-09140
OAAI
Combined eff ect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial
2016-10-01157
PREAI